[1] |
Shah D, Mandot A, Cerejo C, et al. The outcome of primary hepatic neuroendocrine tumors: A single-center experience[J]. J Clin Exp Hepatol, 2019, 9(6): 710-715.
|
[2] |
Song JE, Kim BS, Lee CH. Primary hepatic neuroendocrine tumor: A case report and literature review[J]. World J Clin Cases, 2016, 4(8): 243-247.
|
[3] |
Xia Y, Zhang L, Wu H, et al. Primary hepatic neuroendocrine tumor with multiple liver metastases: A case report with literature review[J]. J Int Med Res, 2020, 48(6): 300060520932114.
|
[4] |
Frilling A, Sotiropoulos GC, Li J, et al. Multimodal management of neuroendocrine liver metastases[J]. HPB (Oxford), 2010, 12(6): 361-379.
|
[5] |
Lambrescu IM, Martin S, Cima L, et al. Primary hepatic neuroendocrine tumor after 4 years tumor-free follow-up[J]. J Gastrointestin Liver Dis, 2015, 24(2): 241-244.
|
[6] |
Campana D, Nori F, Piscitelli L, et al. Chromogranin A: is it a useful marker of neuroendocrine tumors?[J]. J Clin Oncol, 2007, 25(15): 1967-1973.
|
[7] |
Huang HF, Jin PP, Yang HJ, et al. Primary hepatic neuroendocrine tumor mimicking ruptured hepatocellular carcinoma with AFP elevation: A case report and literature review[J]. Onco Targets Ther, 2020, 13: 975-979.
|
[8] |
Huang K, Lan Z, Chen W, et al. Hepatectomy and pneumectomy combined with targeted therapy for primary hepatic neuroendocrine carcinoma: case report and review of the literature[J]. Front Surg, 2022, 9: 920276.
|
[9] |
李家开,王敏,袁静, 等. 肝脏原发性神经内分泌肿瘤的CT和磁共振成像表现[J]. 中华肿瘤杂志, 2017, 39(8): 600-606.
|
[10] |
高伟华,向晓星,王甦, 等. 以肝脏弥漫性肿大为特征的肝脏原发性神经内分泌肿瘤二例[J/CD]. 中华消化病与影像杂志(电子版), 2017, 7(6): 278-279.
|
[11] |
Mitamura K, Yamamoto Y, Tanaka K, et al. (18)F-FDG PET/CT imaging of primary hepatic neuroendocrine tumor[J]. Asia Ocean J Nucl Med Biol, 2015, 3(1): 58-60.
|
[12] |
DeLuzio MR, Barbieri AL, Israel G, et al. Two cases of primary hepatic neuroendocrine tumors and a review of the current literature[J]. Ann Hepatol, 2017, 16(4): 621-629.
|
[13] |
Collins K, Newcomb PH, Cartun RW, et al. Utility and limitations of albumin mRNA in situ hybridization detection in the diagnosis of hepatobiliary lesions and metastatic carcinoma to the liver[J]. Appl Immunohistochem Mol Morphol, 2021, 29(3): 180-187.
|
[14] |
Morishita A, Yoneyama H, Nomura T, et al. Primary hepatic neuroendocrine tumor: A case report[J]. Mol Clin Oncol, 2016, 4(6): 954-956.
|
[15] |
Li YF, Zhang QQ, Wang WL. Clinicopathological characteristics and survival outcomes of primary hepatic neuroendocrine tumor: A surveillance, epidemiology, and end results (SEER) population-based study[J]. Med Sci Monit, 2020, 26: e923375.
|
[16] |
Qu C, Qu LL, Zhu CZ, et al. Treatment of primary hepatic neuroendocrine tumors with associating liver partition and portal vein ligation for staged hepatectomy (ALPPS): A case report and literature review[J]. Medicine (Baltimore), 2018, 97(37): e12408.
|
[17] |
Li S, Niu M, Deng W, et al. Efficacy of chemotherapy versus transcatheter arterial chemoembolization in patients with advanced primary hepatic neuroendocrine carcinoma and an analysis of the prognostic factors: A retrospective study[J]. Cancer Manag Res, 2021, 13: 9085-9093.
|